Clinical Trial

Alzheimer's Disease THErapy With NEuroaid II

Study acronym: ATHENE II
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
ATHENE II is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial designed to evaluate the efficacy and safety of MLC901 in subjects with mild to moderate Alzheimer's disease, as well as its effects on plasma biomarkers compared to placebo.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-22.
Trial Details
NCT Number NCT07191028
Lead Sponsor Moleac Pte Ltd.
Collaborators: National University Hospital, Singapore
Conditions Alzheimer's Disease Dementia
Enrollment 350 participants
Start Date 2026-08
Primary Completion 2029-02 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-12